Ozempic boosts cardiometabolic markers, falls short for fibrosis in NASH-related cirrhosis
LONDON — Ozempic improved cardiometabolic parameters and markers of liver injury yet failed to improve liver fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis,…